201 related articles for article (PubMed ID: 21212410)
1. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
Rushworth SA; Bowles KM; MacEwan DJ
Cancer Res; 2011 Mar; 71(5):1999-2009. PubMed ID: 21212410
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.
Pullarkat V; Meng Z; Tahara SM; Johnson CS; Kalra VK
Hemoglobin; 2014; 38(3):188-95. PubMed ID: 24670032
[TBL] [Abstract][Full Text] [Related]
3. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.
Chen Z; Pittman EF; Romaguera J; Fayad L; Wang M; Neelapu SS; McLaughlin P; Kwak L; McCarty N
PLoS One; 2013; 8(8):e69126. PubMed ID: 23936317
[TBL] [Abstract][Full Text] [Related]
4. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
Fang J; Rhyasen G; Bolanos L; Rasch C; Varney M; Wunderlich M; Goyama S; Jansen G; Cloos J; Rigolino C; Cortelezzi A; Mulloy JC; Oliva EN; Cuzzola M; Starczynowski DT
Blood; 2012 Jul; 120(4):858-67. PubMed ID: 22685174
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Corrales-Medina FF; Manton CA; Orlowski RZ; Chandra J
Leuk Res; 2015 Mar; 39(3):371-9. PubMed ID: 25612941
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.
Matondo M; Bousquet-Dubouch MP; Gallay N; Uttenweiler-Joseph S; Recher C; Payrastre B; Manenti S; Monsarrat B; Burlet-Schiltz O
Leuk Res; 2010 Apr; 34(4):498-506. PubMed ID: 19811823
[TBL] [Abstract][Full Text] [Related]
8. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
[TBL] [Abstract][Full Text] [Related]
9. Characterization of bortezomib-adapted I-45 mesothelioma cells.
Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
[TBL] [Abstract][Full Text] [Related]
10. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
11. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
[TBL] [Abstract][Full Text] [Related]
12. Antioxidant-induced phosphorylation of tyrosine 486 leads to rapid nuclear export of Bach1 that allows Nrf2 to bind to the antioxidant response element and activate defensive gene expression.
Kaspar JW; Jaiswal AK
J Biol Chem; 2010 Jan; 285(1):153-62. PubMed ID: 19897490
[TBL] [Abstract][Full Text] [Related]
13. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
[TBL] [Abstract][Full Text] [Related]
14. XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells.
Carter BZ; Mak DH; Wang Z; Ma W; Mak PY; Andreeff M; Davis RE
Leuk Res; 2013 Aug; 37(8):974-9. PubMed ID: 23669290
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells.
Du ZX; Yan Y; Zhang HY; Liu BQ; Gao YY; Niu XF; Meng X; Wang HQ
J Clin Endocrinol Metab; 2011 May; 96(5):E763-71. PubMed ID: 21346076
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
[TBL] [Abstract][Full Text] [Related]
18. Bach1 differentially regulates distinct Nrf2-dependent genes in human venous and coronary artery endothelial cells adapted to physiological oxygen levels.
Chapple SJ; Keeley TP; Mastronicola D; Arno M; Vizcay-Barrena G; Fleck R; Siow RCM; Mann GE
Free Radic Biol Med; 2016 Mar; 92():152-162. PubMed ID: 26698668
[TBL] [Abstract][Full Text] [Related]
19. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]